# β-Elemene

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/elemene
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-28
**Evidence Score:** 2 / 10
**Category:** Compound
**Also Known As:** Beta-elemene, β-Elemene sesquiterpene, Curcuma elemene, Wenyujin elemene, Elemene beta, Chinese elemene, Turmeric elemene, Zhejiang elemene

## Overview

β-Elemene is a naturally occurring sesquiterpene compound extracted primarily from Curcuma wenyujin and other Zingiberaceae plants. It exerts anticancer activity by inducing [mitochondrial](/ingredients/condition/energy)-mediated apoptosis, inhibiting tumor cell proliferation, and modulating cell cycle arrest at the G2/M phase.

## Health Benefits

• Enhances clinical efficacy in non-small cell lung cancer when combined with chemotherapy, as shown in a meta-analysis of 15 RCTs involving 1,410 patients.
• Improves response rates in acute myeloid leukemia, achieving an 80.8% effective rate in a study of 120 patients.
• Increases overall efficacy in controlling malignant pleural effusion, demonstrated in a pooled analysis of 46 trials with 2,992 patients.
• Promotes apoptosis and impairs [glucose metabolism](/ingredients/condition/weight-management) in cancer cells, based on in vitro studies.
• Downregulates cancer stem cell markers, enhancing chemotherapy sensitivity, as seen in preclinical studies.

## Mechanism of Action

β-Elemene triggers intrinsic apoptosis by downregulating Bcl-2 and upregulating Bax, disrupting [mitochondrial](/ingredients/condition/energy) membrane potential and activating caspase-3 and caspase-9 cascades. It inhibits tumor proliferation by suppressing cyclin B1 and CDK1 expression, causing G2/M phase cell cycle arrest. Additionally, β-Elemene inhibits the PI3K/Akt/mTOR and MAPK/ERK signaling pathways, reducing cancer cell survival, migration, and angiogenesis mediated through VEGF suppression.

## Clinical Summary

A meta-analysis of 15 randomized controlled trials involving 1,410 patients demonstrated that β-Elemene combined with chemotherapy significantly enhances clinical efficacy in non-small cell lung cancer, improving tumor response rates and quality of life compared to chemotherapy alone. In a clinical study of 120 acute myeloid leukemia patients, β-Elemene injection achieved an effective rate of 80.8%, outperforming standard treatment arms. Evidence is primarily derived from Chinese clinical trials, which often vary in blinding quality and reporting standards, warranting cautious interpretation. Overall, the body of evidence supports adjunctive use in oncology settings, but large-scale, internationally registered phase III trials are still needed to confirm findings.

## Nutritional Profile

β-Elemene is not a nutrient or food substance but a sesquiterpene bioactive compound (molecular formula: C₁₅H₂₄; molecular weight: 204.35 g/mol) extracted primarily from the rhizome of Curcuma wenyujin (温郁金), a traditional Chinese medicinal plant related to turmeric. It is classified as a terpene hydrocarbon and is administered pharmaceutically rather than consumed as part of a diet. Key details: • **Chemical class:** Sesquiterpene (1-methyl-1-vinyl-2,4-diisopropenylcyclohexane); exists as one of three isomers (α-, β-, γ-elemene), with β-elemene being the most pharmacologically studied. • **Natural source concentration:** Present in Curcuma wenyujin essential oil at approximately 3–8% of total volatile oil content; also found in smaller quantities in Curcuma zedoaria, celery seed oil, and certain citrus peel oils. • **Pharmaceutical formulations:** Available as β-Elemene Injection (elemene emulsion injection, typically 20 mg/mL) and oral emulsion in Chinese clinical settings (approved by CFDA). Typical clinical doses range from 400–800 mg/day intravenously or 1,200–1,600 mg/day orally. • **Macronutrients/Micronutrients:** Not applicable — β-elemene contains no proteins, carbohydrates, fats, vitamins, minerals, or dietary fiber. It is a pure lipophilic hydrocarbon compound with zero caloric/nutritional contribution. • **Bioavailability notes:** β-Elemene is highly lipophilic (logP ~4.6) with poor aqueous solubility, necessitating emulsion-based delivery systems for clinical use. Oral bioavailability is relatively low due to extensive first-pass hepatic [metabolism](/ingredients/condition/weight-management); injectable emulsion formulations significantly improve systemic bioavailability. It undergoes hepatic cytochrome P450-mediated oxidative metabolism. The compound crosses the blood-brain barrier to some extent, which has been explored in glioma research. • **Key bioactive properties (non-nutritional):** Functions primarily as an antineoplastic agent via multiple mechanisms including cell cycle arrest (G2/M phase), induction of apoptosis, inhibition of angiogenesis, reversal of multidrug resistance (downregulation of P-glycoprotein), and [immunomodulat](/ingredients/condition/immune-support)ion (enhancement of T-cell and NK-cell activity). It is not considered a dietary supplement or nutritional compound.

## Dosage & Preparation

In vivo studies used 5 mg/kg intraperitoneally daily for seven days in lung cancer models. In vitro effects begin at 5 μg/mL. Dosage in clinical practice is typically via elemene injections. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

β-Elemene is generally well tolerated when administered as a clinical injection formulation, with the most commonly reported adverse effects including mild phlebitis, fever, and gastrointestinal symptoms such as nausea and vomiting. Hypersensitivity reactions have been reported with intravenous β-Elemene emulsion preparations, and premedication protocols are sometimes employed in clinical settings. Potential pharmacokinetic interactions exist with chemotherapy agents metabolized via CYP450 enzymes, though specific interaction data remain limited. β-Elemene is not recommended during pregnancy or lactation due to insufficient safety data, and patients on anticoagulants or immunosuppressants should consult a physician before use.

## Scientific Research

Clinical evidence primarily comes from randomized controlled trials conducted in China, with varying methodological quality. A 2019 meta-analysis (PMID: Not Available) of 15 trials confirmed its efficacy in lung cancer. Further research highlights its potential in acute myeloid leukemia and malignant pleural effusion.

## Historical & Cultural Context

β-Elemene is derived from Curcuma wenyujin, used in traditional Chinese medicine for various ailments. Its inclusion in modern cancer therapy reflects its historical use as a medicinal agent.

## Synergistic Combinations

Curcumin, Cisplatin, Oxaliplatin, Homoharringtonine, Arabinosylcytosine

## Frequently Asked Questions

### What is β-Elemene used for?

β-Elemene is primarily used as an adjunctive anticancer agent, most commonly alongside conventional chemotherapy in cancers such as non-small cell lung cancer and acute myeloid leukemia. Clinical data from a meta-analysis of 15 RCTs involving 1,410 patients show it significantly improves tumor response rates and patient quality of life when combined with standard chemotherapy regimens.

### How does β-Elemene fight cancer cells?

β-Elemene induces cancer cell death through the intrinsic mitochondrial apoptosis pathway by downregulating the anti-apoptotic protein Bcl-2 and upregulating pro-apoptotic Bax, ultimately activating caspase-3 and caspase-9. It also blocks cancer cell replication by causing G2/M phase cell cycle arrest via suppression of cyclin B1 and CDK1, and further inhibits tumor growth by disrupting the PI3K/Akt/mTOR and VEGF-driven angiogenesis pathways.

### What plant does β-Elemene come from?

β-Elemene is a sesquiterpene compound primarily extracted from the rhizomes of Curcuma wenyujin, a member of the Zingiberaceae (ginger) family widely used in traditional Chinese medicine. It is also found in smaller concentrations in other Curcuma species and various aromatic plants, but pharmaceutical-grade β-Elemene is most commonly sourced from Curcuma wenyujin for clinical formulations.

### What is the effective dose of β-Elemene in clinical studies?

In Chinese clinical trials, β-Elemene is typically administered as an intravenous emulsion injection at doses ranging from 400 to 600 mg per day, often given over a treatment cycle of 21 to 28 days in oncology settings. Oral capsule formulations have also been studied, though intravenous administration remains the most documented route in published RCTs; standardized dosing guidelines for supplemental or outpatient use have not yet been internationally established.

### Are there any side effects of β-Elemene?

The most frequently reported side effects of β-Elemene injection include local phlebitis at the infusion site, low-grade fever, and mild gastrointestinal disturbances such as nausea and vomiting. Hypersensitivity or allergic reactions have been documented with the intravenous emulsion formulation, and patients are sometimes pre-treated with antihistamines in clinical protocols. Serious adverse events are considered uncommon based on available trial data, but long-term safety has not been rigorously evaluated in large international studies.

### Does β-Elemene interact with chemotherapy drugs?

β-Elemene is specifically studied in combination with conventional chemotherapy agents for cancer treatment, and clinical evidence suggests it enhances rather than interferes with chemotherapy efficacy. A meta-analysis of 15 randomized controlled trials involving 1,410 patients with non-small cell lung cancer demonstrated improved response rates when β-Elemene was used alongside chemotherapy. However, because β-Elemene may potentiate chemotherapy effects, its use should be coordinated with an oncologist to avoid unintended drug interactions or toxicity amplification.

### What does the clinical evidence show about β-Elemene's effectiveness?

Clinical research demonstrates substantial efficacy across multiple cancer types, with a pooled analysis of 46 trials showing improved control of malignant pleural effusion and a meta-analysis of 15 RCTs (1,410 patients) confirming enhanced outcomes in non-small cell lung cancer when combined with chemotherapy. In acute myeloid leukemia specifically, β-Elemene achieved an 80.8% effective response rate in a study of 120 patients. While these results are promising, most studies are from Asian institutions, and additional large-scale trials in Western populations would strengthen the evidence base.

### Who are the ideal candidates for β-Elemene supplementation?

β-Elemene is primarily indicated for patients with specific malignancies—particularly non-small cell lung cancer, acute myeloid leukemia, and malignant pleural effusion—as an adjunctive therapy alongside conventional chemotherapy. Current evidence supports its use in adult cancer patients under medical supervision rather than as a preventive supplement in healthy individuals. Because β-Elemene's effects are demonstrated in oncology settings, it is not recommended for general wellness or non-cancer populations without clinical justification.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*